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Abstract Treating metastatic osteosarcoma (OS) remains
a challenge in oncology. Current treatment strategies target
the primary tumour rather than metastases and have a
limited efﬁcacy in the treatment of metastatic disease.
Metastatic cells have speciﬁc features that render them less
sensitive to therapy and targeting these features might
enhance the efﬁcacy of current treatment. A detailed study
of the biological characteristics and behaviour of metastatic
OS cells may provide a rational basis for innovative
treatment strategies. The aim of this review is to give an
overview of the biological changes in metastatic OS cells
and the preclinical and clinical efforts targeting the dif-
ferent steps in OS metastases and how these contribute to
designing a metastasis directed treatment for OS.
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Osteosarcoma (OS) is the most common primary malignant
bone tumour in children and adolescents. The estimated
incidence rate worldwide is 4/million/year, with a peak
incidence at the age of 15–19 years [1]. In OS there is a
high tendency to metastatic spread. Approximately 20% of
patients present with lung metastases at initial diagnosis
and, additionally, in 40% of patients metastases occur at a
later stage. Eighty percent of all metastases arise in the
lungs, most commonly in the periphery of the lungs, and
exhibit resistance to conventional chemotherapy [2–7]. The
5-year survival rate for OS patients with metastases is 20%
compared to 65% for patients with localised disease and
most deaths associated with OS are the result of metastatic
disease [5, 8–11].
For patients with pulmonary metastasis, especially those
who have metastasis at initial diagnosis, the combination of
radical metastasectomy and chemotherapy offers the best
outcome and even potential cure. Nevertheless, recurrent
development of pulmonary metastases after initial radical
metastasectomy is reported to be high and repeated
metastasectomies are sometimes performed. As metasta-
sectomy does yield an improved survival in most patients it
should therefore always be performed when feasible [2, 4,
12–14].
In order to improve survival, the ultimate questions to be
answered are: Why does OS metastasize, particularly to the
lungs? And, more importantly: Why does therapy fail in
metastatic disease? In this regard, we hypothesise that drug
resistance is a key issue in the failure to control metastatic
disease. It has been shown that OS lung metastases display
a biological behaviour different from the primary tumours
[2, 14–27]. Metastases are comprised of cell clones that
differ from primary tumours with respect to ploidy, enzyme
proﬁle, karyotype and chemosensitivity [2, 28–32]. Ther-
apeutic regimens that target primary tumours are therefore
unlikely to be successful in the treatment of metastatic
disease.
Metastasis is considered to be the ﬁnal though most
critical step in tumorigenesis of malignant tumours [33].
The metastatic cancer cells subsequently complete the
following steps: Invasion through the extracellular host
matrix and entrance into the circulation (I), survival in the
circulation (II) and evasion of the host immune system
(III), arrest and extravasation at a target organ site (IV),
adherence and survival in the target organ microenviron-
ment (V, VI) and ﬁnally formation of neovasculature to
allow growth at the target organ site (VII) [14, 33–36].
Each step is of equal importance and must be fully com-
pleted by the tumour cell to achieve successful metastasis.
The altered biological behaviour in metastatic cells is the
result of speciﬁc molecular changes. We will discuss each
of these speciﬁc steps with special attention to the mole-
cules involved in OS metastasis (Table 1) and implications
for therapy. Over the last decade, much research has been
performed to try to unravel the biology of OS metastasis
and many (pre)clinical studies have attempted to discover
new treatment options for metastatic OS. For example,
gene expression proﬁling of metastatic cells using a cDNA
microarray approach has identiﬁed genes responsible for
metastasis [27, 37–39]. Also, expression levels of speciﬁc
proteins in OS lung metastases have been analysed. In
these studies, expression levels of proteins involved in
metastases link the molecular aberrancies to clinical out-
come in terms of survival rates. These alterations may also
provide novel drug targets [21, 23, 25, 36, 40–42]. Table 2
summarises (pre)clinical studies for treating OS
metastases.
The aim of this review is to give an overview of the
biology of metastatic OS cells and of (pre)clinical efforts
targeting the different steps in OS metastases and how
these may contribute to designing a metastasis directed
treatment for OS.
OS metastasis
(I) Migration and invasion
Migration of cells away from the primary tumour and
invasion through the extracellular matrix (ECM) towards
the bloodstream is considered the ﬁrst step contributing to
metastasis. In OS, it has been described that MetalloPro-
teinases (MMPs) 2 and 9 and m-Calpain play a role in
degradation of the ECM [10, 14, 16, 18, 19, 27, 34, 35,
43–46]. Also, the Wnt/b-catenin pathway and Src-kinase
are implicated as inducers of migration [9, 35, 46, 47]. In
OS, Notch is a relatively recently identiﬁed pathway and
has been identiﬁed as a promoter of invasion in OS. In
highly metastatic OS cell lines there is an upregulation of
the Notch1 and Notch2 receptor, as well as the Notch
induced gene Hes1. In patient samples, expression of the
Hes1 gene inversely correlated with survival [41, 48–50].
(Pre)clinical studies: Notch
In a preclinical setting, downregulation of the Notch sig-
nalling pathway has been shown to impair the invasiveness
of cell lines, but has no effect on cell proliferation or in
vitro tumorigenesis. Notch-inhibited cell lines had less
potential to form lung metastases in an orthotopic mouse
model when compared to untreated cell lines. The exact
mechanism through which inhibition of the Notch pathway
and its target gene Hes1 leads to reduced invasion still
remains unknown [41, 50].
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Dissemination of cancer cells through the body requires the
cells to survive in the circulation. Non-malignant cells, as
well as non-metastatic tumour cells, become apoptotic after
loss of cell–cell adhesions or interaction with the ECM in
their original tissue. This speciﬁc mode of apoptosis is
called anoikis. One reason for this type of apoptosis to
occur is that Integrin signalling ceases to exist in solitary
cells. Under adherent conditions, survival is often mediated
through Integrin signalling pathways in which Focal
adhesion kinase (FAK) is a central player. FAK activates
the important PI3K/Akt survival pathway. Metastatic
tumour cells evade anoikis by intrinsically activated sur-
vival pathways via for example PI3K or Akt signalling,
independent of extrinsic Integrin and FAK signalling
[9, 14, 16, 51]. Src kinase can also activate the PI3K/Akt
and the Ras/MAPK survival pathways independent of FAK
Table 1 Steps of metastasis in
OS and molecular alterations
that contribute to each process
Steps of metastasis Molecular involvement References
I Migration and invasion MMPs [10, 14, 16, 18, 19, 27, 34, 35, 44–
46]
m-Calpain [35, 43]
Wnt [9, 35, 46, 47]
Src [35, 44]
Notch [41, 48–50]
II (a) Anoikis resistance PI3K/Akt [9, 14, 16, 51]
Src/PI3k/Akt [9, 14, 16, 44]
Src/Ras/MAPK [18, 35]
NF-jB[ 27]
Wnt/b-catenin [14]
BcL family [9, 35, 51]
(b) Apoptosis resistance Src [9, 16, 18, 35, 44]
NF-jB[ 27, 44, 51, 67]
Wnt/b-catenin [14, 17, 19, 46, 47, 53, 54]
Fas/FasL [5, 23, 28, 36, 55, 56]
III Evasion of immune system HLA-1 [14, 60]
IL-10 [14]
Fas [62]
IV Arrest and extravasation CXCR4-CXCL12 [9, 10, 14, 15, 22, 42, 69]
CXCR3-CXCL9-11 [10]
CXCR4/MMPs [9, 10, 15]
CXCR3-4/Erk/NF-jB[ 10, 67]
V Adherence Ezrin/MAPK/Akt [14, 21, 25, 35]
Ezrin/b4-Integrin/PI3K [70]
CD44/Akt/mTOR [14, 19, 21]
VI Dormancy Integrin-a5b1[ 73, 74]
Integrin-a5b1/Erk/p38 [14, 35]
Bcl-XL [14, 35]
IGF/PI3K [75]
ECM [73, 74]
VII Angiogenesis and
proliferation
EGFR. PDGFR, VEGF, IGFR,
TGF-b
[9, 14, 35, 40, 68, 77, 78, 81]
MMPs [9, 44, 78]
VEGF/Erk/NF-jB[ 35, 68]
VEGF/PI3K [35, 40]
EGFR/Src/Ras/MAPK/STAT3 [9, 18]
Src [14, 35, 44]
Integrin/PI3K/Erk1-2 [9, 35, 67, 75]
Wnt/b-catenin/CyclinD-Survivin [46, 52]
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123signalling and thus stimulate ainoikis resistance [9, 14, 16,
18, 35, 44, 51]. Other survival mechanisms are also of
importance in the evasion of ainoikis, such as activation the
nuclear factor-kappa B (NF-jB) pathway [27, 51] and
Wnt-mediated upregulation of the b-catenin activity. High
levels of b-catenin expression have been shown to be
associated with a metastatic phenotype in OS [14, 19, 20,
46]. Finally, overexpression of anti-apoptotic genes such as
Bcl-2, Bcl-XL or FAK is exploited by solitary metastatic
cells to obtain a survival beneﬁt [9, 35, 51].
(IIb) Apoptosis resistance
The survival of tumour cells through all stages of metas-
tasis (not only in the bloodstream) is paramount to suc-
cessful metastasis. Mechanisms involved in apoptosis
resistance throughout metastasis include activation of the
Src and NF-jB pathways and the overexpression of anti-
apoptotic genes [9, 44, 46, 51, 52]. Wnt-signalling is also
involved in resistance to apoptosis throughout other steps
of metastasis and is considered to be important for tumour
progression in general. Upon binding of Wnt to one of its
receptors, b-catenin degradation in the cytoplasm is pre-
vented. After b-catenin is stabilised it translocates to the
nucleus where it co-regulates oncogene transcription and
cell cycle progression and hence promotes survival and
proliferation [14, 17, 46, 47, 53, 54].
In established metastases, the tumour cells are con-
fronted with receptor-mediated cell death. Binding of Fas
on the surface of metastatic cells to its Fas-ligand (FasL)
expressed constitutively on lung tissue, activates the Fas-
apoptosis pathway and leads to cell death. Cross-linkage of
Table 2 Preclinical and
clinical studies targeting
speciﬁc molecules in OS
metastasis
Steps of metastasis Target Drug References
Preclinical
I Migration and Invasion Notch [41, 50]
II (a) Anoikis resistance
(b) Apoptosis resistance Preclinical
Wnt [46, 52]
Src [18]
Clincial
Src
Dasatinib [60]
www.clinicaltrials.gov/NCT00752206
III Evasion of
immune system
Preclinical
Fas
IL12 [36, 56, 62]
IL18 [63]
Gemcitabine [55]
Clinical
Fas
Liposomal MTP-PE [64]
IFN-a [61, 66]
IV Arrest and extravasation Preclinical
CXCR4 [22]
CXCR3 [10]
V Adherence Preclinical
Ezrin [21, 25, 45, 70]
VI Dormancy
VII Proliferation and
angiogenesis
Preclinical
Endostatin [83]
IGF-1R [79, 84]
Clinical
IGF-1R
OncoLar [78]
R1507 www.clinicaltrials.gov/NCT00642941
SCH717454 www.clinicaltrials.gov/NCT00617890
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55]. Resistance to death-receptor-induced apoptosis is
commonly seen and is highly important for the successful
maintenance of metastases. The Fas/Fas-ligand pathway is
a death receptor pathway that is often down-regulated in
metastatic cell populations, rather than in primary tumours
[23, 28, 36]. The Fas pathway is also of inﬂuence on
chemotherapy-induced apoptosis and thus on its therapeu-
tic efﬁcacy [56]. Much (pre) clinical research has been
performed concerning this pathway in metastatic OS and
promising results have been obtained. These results are
discussed following the section on immune evasion, since
the Fas pathway plays a role in that as well.
Thus, apoptosis resistance is very much exploited by the
metastatic cell and this feature is likely to contribute to
resistance to therapy in metastatic OS [51, 52]. The failure
to induce apoptosis upon treatment is thought to be the
result of a misbalance between pro- and anti-apoptotic
signalling. Restoration of this balance, thereby creating an
environment in favour of pro-apoptotic signalling could
theoretically enhance treatment with cytotoxic agents [9,
35, 45, 51, 56–58].
(Pre)clinical studies: Wnt and Src
The Wnt-pathway is a putative therapeutic target because a
majority of OS samples show aberrant activation of this
pathway, leading to the transcription of oncogenes and cell
cycle progression. This in turn leads to proliferation and
enhanced survival [46, 53, 59]. When targeting the Wnt-
pathway, activating mutations in downstream molecules for
example b-catenin can be of negative inﬂuence as it may
bypass Wnt inhibition and preserve the invasive phenotype
of the metastatic cell [19]. A preclinical study byLeow et al.
[52] has shown that inhibition of the Wnt/b-catenin path-
way resulted in lower levels of nuclear b-catenin, resulting
in a decreased expression of b-catenin target genes. This led
to an inhibition of migratory potential through downregu-
lation of MMP-9, and a decrease in expression of Cyclin-D,
c-myc and Survivin. The latter was responsible for an anti-
proliferative effect and an increase in cell death. These
results were recently conﬁrmed by Rubin et al. [46], who
showed that re-expression of Wnt inhibitory factor 1 (WIF-1),
a secreted Wnt-antagonist, inhibited Wnt signalling and
reduced tumour growth and metastasis in OS mouse mod-
els. These results show a possible therapeutic beneﬁt of
Wnt-pathway disruption in the treatment of metastatic OS.
Src-kinase is a kinase that is involved in almost all steps
of cancer metastasis, namely in proliferation, adhesion,
migration, survival and angiogenesis [44]. Based on its
multi-step involvement in metastasis, it could be an inter-
esting therapeutic target in OS metastasis. Pre-clinical
work shows that Src inhibition with Dasatinib effectively
inhibits Src phosphorylation in primary tumours; however,
it did not impair the development of pulmonary metastases.
Histopathological analysis of both OS primary tumours and
lung nodules showed minimal Src-kinase phosphorylation
after treatment with Dasatinib. However, Src-kinase
phosphorylation was low in untreated lung metastasis as
well. This suggests that Dasatinib was effective in inhib-
iting Src-pathway activation in OS cells, but it is not clear
what the phosphorylation status is during the stages of OS
metastasis and how this inﬂuences the process [18]. The
use of Dasatinib in patients with advanced (osteo)sarcomas
was examined recently by the SARC (Sarcoma Alliance for
Research through Collaboration) in a phase II clinical trial.
Disappointingly, preliminary results show no treatment
effect of Dasatinib as a single agent in patients with overt
lung metastases [60]. The same group is looking into the
effectiveness of Src inhibition with a more speciﬁc Src-
kinase inhibitor (Saracatinib) to obtain progression free
survival among patients with resectable OS lung metasta-
ses (clinicaltrials.gov/NCT00752206).
(III) Evasion of the immune system
Another important precondition for the survival of meta-
static cells is the evasion of the host immune surveillance
throughout all the steps of metastasis. Tumour cells, either
circulating or at the site of metastases, can modulate the
immune system of the host in order to achieve a survival
advantage. Down-regulation of cell surface receptor HLA
class 1 is one of such mechanisms. This impairs the recog-
nition of tumour cells by the host cytotoxic T-lymphocytes.
Tumour cells can also induce the production of immuno-
suppressivemoleculessuchasIL-10[14,61].Modulationof
the immune system such that it recognizes and destroys
(circulating) tumour cells would be a successful anti-meta-
static treatment. Interferons are cytokines that can affect the
recognition of tumour cells by the immune system by
inﬂuencing the (re)expression of HLA molecules on the cell
surface. Interferons also exert an anti-proliferative effect on
OS cells through pathways that are yet unknown [61]. The
balance between the intrinsic downregulation of HLA
molecules of the tumour cells and the effect of Interferon
stimulation will eventually determine whether the circulat-
ing tumour cell is cleared by the immune system or not.
Fas also plays a role in immune evasion. Fas expression
leads to recognition by, and activation of cytotoxic natural
killer (NK) cells and promotes elimination from the cir-
culation by the host immune system. Successful down-
regulation of the Fas molecule on the cell surface or cor-
ruption of downstream elements in the Fas pathway pro-
vides metastatic tumour cells with a survival advantage in
the circulation and leads to an increase in metastatic
potential. Patient samples from pulmonary OS metastases
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absence of Fas expression correlates with disease pro-
gression and poor survival outcome [23, 36, 55, 62].
(Pre)clinical studies: Fas
As the Fas receptor pathway is so important in the survival
of metastatic cells, it is an attractive therapeutic target.
Restoration of the Fas death pathway has been tried with
success in preclinical models. Interleukin-12 (cytokine)
therapy can achieve a dose-dependent upregulation of Fas
on the surface of OS cells as well as a stimulation of
cytotoxic T-cells and NK-cells. This renders the metastatic
cells more sensitive to Fas-induced cell death in the
microenvironment of the lung and enhances clearage of the
cells from the circulation by the host immune system [36].
A drawback is the potent immunostimulatory effect of
Interleukin-12 that can induce severe adverse effects after
systemic administration in patients [56, 62].
In an in vivo experiment, intranasal administration of
IL-12 resulted in Fas overexpression on OS lung metasta-
ses, leading to a decrease in tumour burden. Combination
therapy with Ifosfamide, which induces the expression of
FasL on the tumours, could further augment anti-tumour
effect [28, 56].
IL-18 was reported to have similar effects on the acti-
vation of T-cells and NK-cells, as well as induction of the
expression of FasL on already Fas expressing tumours.
This compound did not, however, exert an anti-tumour
effect in mice bearing OS lung metastases [63].
Gemcitabine is an agent that upregulates Fas-expression
when administered as an aerosol therapy in mice bearing
OS lung metastases. Gemcitabine aerosol therapy has been
shown to effectively reduce size and number of pulmonary
metastases [5, 55].
Liposomal MTP-PE (muramyl tripeptide phosphatidyl
ethanolamine) is a promising agent for clinical use as it can
induce endogenous IL-12 production and thus provide an
up-regulation of Fas on OS cells but without the systemic
toxicity encountered when exogenous IL-12 is adminis-
tered to patients [28]. MTP-PE is a synthetic analogue of a
component of bacterial cell walls. As an immunomodula-
tory agent it can also stimulate monocytes and macro-
phages to exert anti-tumour activity. The Children’s
Oncology Group performed a prospective randomised
phase III clinical trial with this compound in patients with
high-grade conventional OS with metastases at diagnosis.
Treatment with liposomal MTP-PE improved overall sur-
vival, irrespective of the chemotherapy regimen. These
data are promising and suggest that there is a critical role
for the Fas death pathway in chemotherapy response which
can be exploited in clinical practice to enhance the efﬁcacy
of chemotherapy in OS [40, 64, 65].
(Pre)clinical studies: Immune modulation
Modulation of the immune system to exert anti-tumour
activity by the addition of interferon-a (IFN-a)a sa
maintenance treatment after standard chemotherapeutic
treatment is currently under investigation in the EURA-
MOS-1 trial, which is an initiative of the European and
American Osteosarcoma Study Group [66]. IFN-a is
immunomodulatory and able to stimulate a host-anti-
tumour immune reaction and induce anti-proliferative
signalling via the JAK/STAT1 pathway [58]. Accrual of
patients for this worldwide trial is due to be completed in
July 2011 [61, 66].
(IV) Arrest and extravasation
The mechanism of arrest of metastatic tumour cells at the
distant organ sites remains controversial. One hypothesis is
that metastatic cells are larger than ordinary cells in the
circulation and that they become trapped in the microcir-
culation of a capillary bed. When trapped they form micro-
embolisms and start interaction with the local environment.
It is striking, however, that different tumour types have an
organ speciﬁc preference for metastasis. The metastatic
behaviour of OS is very distinct as over 80% of all
metastases arise in the lungs and other organs usually
remain unaffected. This suggests that the circulating
tumour cell speciﬁcally ‘homes’ to distinct molecules that
are expressed on the endothelium of the organ of prefer-
ence. Although it might be trapped in different capillary
beds throughout the body, it will interact with the surface
molecules on the endothelium of the organ of interest
rather than with endothelium at other sites [35]. There is
evidence of endothelium-speciﬁc tropism in OS [10, 14,
15, 22, 42, 67]. The processes of exit of the circulation and
invasion at the distant organ site are mediated by chemo-
kines and proteinases. Proteinases are responsible for
extravasation whereas chemokines determine the site at
which circulating tumour cells adhere [9, 15]. Chemokines
were initially thought to regulate leukocyte trafﬁcking and
homing, but recently they are also known as important
components in the regulation of site-speciﬁc metastasis as
they bind to G-protein coupled receptors on the plasma
membrane of speciﬁc cells, in the case of OS to receptors
in the lung [14, 42, 67–69]. CXCR-4, a commonly
expressed chemokine in OS, is involved in site-speciﬁc
metastasis. Its sole ligand is CXCL12 which is expressed
abundantly in the lung. Binding of CXCR-4 to CXCL12
allows adherence and extravasation of OS cells in the lung
[9, 10, 14, 15, 22, 42, 69]. Laverdiere et al. [42] found that
CXCR-4 expression levels in patient samples inversely
correlated to event-free and overall survival. There was a
positive correlation between CXCR-4 expression in
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diagnosis. Interestingly, expression levels of CXCR-4 were
similar in primary tumours and lung metastases. This
suggests that CXCR-4 expression is not regulated during
metastasis, but is simply present. It could be of predictive
value for the formation of metastasis.
CXCR-3, another chemokine, is expressed by OS as well
as other malignancies. Its ligands are CXCL9, -10 and -11,
all of which are expressed by lung, and this molecule is
thought to co-operate with CXCR-4. Apart from mediating
adherence, the interactions of CXCR-3 and -4 with their
respective ligands also trigger pathways involved in other
necessary events in metastasis, namely in invasion, survival
and proliferation in the secondary tissue [10, 22, 67].
For example, hypoxia upregulates CXCR-3 and -4
expression, which in turn induce the expression of MMP-2
and -9 on the cell surface and modulate the microenviron-
ment into an inﬂammation-like condition, abundant with
growth factors and stimulation of angiogenesis. Further-
more, binding of CXCR-4 to CXCL12 can activate the
NF-jB survival pathway via ERK (Extracellular-signal-
Regulating-Kinase)-signalling and stimulate proliferation
through MAPK signalling. Thus, apart from facilitating
seeding at the distant organs site, chemokines play a very
important role in the modulation of the microenvironment
into a place permissive for the tumour cells to proliferate [9,
10, 15, 67].
(Pre)clinical studies: Chemokines
CXCR-4 is the most important chemokine-player in OS.
Kim et al. [22] have demonstrated a reduction in metastatic
tumour burden in an orthotopic mouse model in which cells
were treated with a CXCR-4 inhibitor prior to injection of
tumour cells into the mice. However, reduction of meta-
static tumour burden without pre-treatment could not been
shown consistently. The authors argue that the critical
event, namely binding of CXCR-4 to CXCL12 with con-
secutive activation of signalling pathways, granting survival
and proliferation, occurs too early in the establishment of
metastases for inhibitory therapy of CXCR-4 to be beneﬁ-
cial for the patient with already existing metastasis. To what
extent CXCR-4 inhibition could be beneﬁcial in a pre-
ventive setting requires additional studies.
CXCR-3 inhibition was tested in an animal model for
human OS lung metastases and showed a signiﬁcant
decrease in the development and progression of pulmonary
lesions compared to the non-treated group [10].
(V) Adherence
Establishment at a distant organ requires the metastatic cell
to connect to its new environment and re-establish cell–cell
adhesions. Ezrin is a membrane-cytoskeleton linker protein
that plays an important role in cell–microenvironment
interaction. It is thought to facilitate anchorage of OS cells
to lung tissue, as well as to enhance survival mechanisms in
the new environment through Integrin mediated activation
of Akt and MAPK survival pathways [14, 21, 25, 35]. The
exact mechanism through which Ezrin mediates metastasis
is not entirely clear, however, recently Wan et al. [70]
discovered that b4-Integrin is an important mediator.
b4-Integrin can bind Ezrin and Ezrin is required for the
maintenance of this protein. b4-Integrin can activate the
PI3K pathway and thus stimulate survival and proliferation
in the newly arrived cells in the lung. b4-Integrin is found to
be highly expressed in OS tumour samples from both pri-
mary and metastatic lesions. Furthermore, it was shown that
b4-Integrin knockdown inhibits the formation of OS lung
metastasis in vivo, and leads to prolonged survival.
High expression of Ezrin correlated with a higher risk of
metastatic relapse and poor survival in OS patients [21, 25].
Furthermore, it was found to be 3-fold overexpressed in lung
metastases in a murine model for OS lung metastases [38].
CD44 is another surface molecule that can form a complex
with Ezrin and correlates with metastasis and poor progno-
sis. Apart from inﬂuence on the cytoskeleton and cell shape,
CD44 controls proliferation, growth arrest and survival via
the Akt/mTOR pathway [14, 19, 21].
(Pre)clinical studies: Ezrin
Suppression of Ezrin with a full-length anti-Ezrin construct
did not inhibit primary tumour growth in a mouse model of
OS, but it effectively inhibited the formation of metastases.
It was speculated that metastatic OS cells express phos-
phorylated Ezrin only early after arrival in the lung, and
this causes limited efﬁcacy of suppression of Ezrin in
readily established metastases, since its essential function
in metastasis, namely connecting with the target organ site
had already been fulﬁlle [21]. Recently however, Ren et al.
[25] suggested that Ezrin phosphorylation is not only
present in the early stage of metastasis, but also late in
tumour progression, at the leading edge of large metastasic
lesions. This ﬁnding was veriﬁed on sections of patient OS
metastases.
Pignochino et al. [45] reported that Sorafenib inhibited
invasion via reduction in MMP-2 production and inhibited
survival via downregulation of Ezrin-activated MAPK/Akt
signalling. Furthermore, Sorafenib could also induce
apoptosis in OS cells through downregulation of members
of the anti-apoptotic Bcl-2 family. Wan et al. [70] showed
that inhibition of Ezrin-related b4-Integrin can reduce
metastasis in a mouse model. Taken together, targeting
Ezrin seems promising in the management of OS lung
metastases.
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Dormancy refers to a prolonged period of survival of single
cells or small micrometastases. OS patients can progress
with metastases after a disease free interval of many years
[71, 72]. This is likely explained by the presence of mi-
crometastases in a dormant state, which at some point are
triggered develop into gross metastases.
Little is known concerning the biological processes reg-
ulating dormancy in OS. The anti-apoptotic gene Bcl-XL is
thought to be involved in the survival of dormant cells, as
well as a5b1-Integrin mediated activation of NF-jB. Fur-
thermore the dormant state is thought to be regulated by the
ratio between the ERK and p38-MAPK proteins, also
steered by Integrin-a5b1 signalling [14, 35, 73, 74].
The mechanisms by which dormant tumour cells are at
one point triggered to start proliferating are yet unac-
counted for, however, the microenvironment is thought to
play a regulatory role. Tumour outgrowth is dependent on
vascularisation, and it has been suggested that endothelial
cells in the microenvironment can both activate dormant
tumour cells through cell-to-cell signalling and induce
angiogenesis for nutrition [74]. The ECM is also thought to
be involved in activation of dormant cells, as it serves as a
source of growth and survival signals. It has been postu-
lated that micrometastases that fail to properly connect to
the ECM remain in the dormant state because they remain
deprived of growth- and angiogenic signalling and go into
quiescence as a means to survive. Anchorage to the ECM
would stimulate cells to convert to a proliferative state via
b1-Integrin signalling [73]. The microenvironment can be
regulated by the tumour cells themselves, but also by host
stromal cells. Leucocytes and macrophages can modulate
the ECM to either form a pro- or anti-angiogenic micro-
environment. Apart from this, other mediating factors can
also be inﬂuenced by stromal cells. For example, Wnt can
be secreted from macrophages, and cytokines secreted by
stromal cells can upregulate the intracellular Wnt/b-catenin
signalling pathway and hence induce survival and prolif-
eration in a late stage in the process of metastasis [9, 35,
54, 73]. Also, bone marrow derived progenitor cells (cre-
ating a ‘pre-metastatic niche’) can modulate the microen-
vironment and thus inﬂuence whether solitary cells or
micrometastases remain dormant or are allowed to progress
[68, 73]. In an effort to elucidate the cellular mechanisms
that establish the switch of dormant to rapidly growing
cells, Almog et al. [75] designed an in vivo model for
dormancy of various cancers, including OS, and performed
gene-expression analysis of cells in the dormant state
versus cells in a proliferative state. They found that during
dormancy, there is an upregulation of anti-angiogenic
proteins. In this pre-angiogenic situation, the tumour cells
would lack the nutrition and oxygen needed to proliferate.
The cells that had switched to the proliferative phenotype
had elevated RNA levels of common cancer pathways such
as PI3K- and IGF-pathways. They also found that Endocan
was upregulated in rapidly proliferating cells, a protein that
is also expressed on tumour endothelial cells. This might
indicate that endothelial changes support the switch of cells
from dormancy into the proliferative state.
Dormancy could have a role in therapy resistance in OS
metastases, however, whether this applies to OS and to what
extent remains unknown. In general, dormancy can bring
about drug resistance because non-proliferating cells are not
so susceptible to conventional treatment. Most treatment
modalities induce DNA damage which is usually more
lethal to rapidly proliferating cells [14, 73, 76]. To intervene
in this step of metastasis seems difﬁcult. Angiogenesis
seems to be an important factor. Elucidation of mechanisms
that steer the switch from dormant to proliferative state may
give some options. If it would be possible to keep the cells
locked in the dormant state, it may grant the patient stable
metastatic disease with prolonged survival.
(VII) Angiogenesis and proliferation
Tumour growth and progression is often restricted by
vascularisation and thus nutrition. Hypoxia leads to the
upregulation of growth factor receptors, angiogenic cyto-
kines and proteolytic enzymes, among which EGFR,
PDGF-R, VEGF, IGF-1R, TGF-b, IL-8 and MMPs, all of
these providing neo-angiogenesis and allowing prolifera-
tion. These molecules can be overexpressed by the tumour
cell population itself, but can also be provided by host
endothelial (progenitor) cells during neo-angiogenesis [9,
14, 35, 40, 44, 68, 77]. Apart from induction of neo-
angiogenesis, VEGF also provides the tumour cells with a
survival beneﬁt via activation of ERK-1/2/NF-jB and
PI3K pathways [35].
Players involved in provision of vasculature and nour-
ishment are often encountered in other processes within OS
metastasis as well. For example, Src-kinase activity is
regulated through various growth factor receptors, such as
EGFR and Integrin receptors. Src activation leads to Ras/
MAPK signalling and activation of the transcription factor
STAT3, allowing cell cycle progression and production of
angiogenic factors such as ﬁbroblast growth factor, VEGF
and IL-8. Src phosphorylation by EGFR especially is
considered to stimulate the onset of hyper-proliferation of
tumour cells and induction of vascular permeability and
neovascularisation [18, 44].
Proliferation of OS cells at a distant organ site is often
mediated by Receptor-Tyrosine-Kinase or Integrin induced
activation of PI3K and ERK1/2 pathways [9, 35, 67].
Alterations in cell cycle regulation can also promote pro-
liferation by facilitating progression through the cell cycle
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123checkpoints and speeding up the cycle. For example, the
Wnt/b-catenin pathway is of inﬂuence on both G1/S and
G2/M progression via activation of Cyclin-D by c-myc and
activation of Survivin respectively [46, 52].
The Insulin-Like-Growth-Factor 1 (IGF-1) Receptor axis
is also implicated in the development of OS. It is striking
that most OS arise during or shortly after puberty. The
inﬂuence of GH and IGF-1 on bone growth steer the lon-
gitudinal growth during the adolescent growth spurt and
contribute to approximately 50% of bone cell proliferation.
As there is a peak incidence of OS during the adolescent
growth spurt, it is conceivable that there could be GH/IGF-1
axis involvement in tumour development. IGF-1R signal-
ling can activate the PI3K/Akt/mTOR pathway and stimu-
late survival and proliferation in tumour cells [40, 77–79].
(Pre)clinical studies: Angiogenesis
As OS is a highly vascularised tumour, a rationale exists to
use this feature as a therapeutic target. High serum-VEGF
levels correlate with metastatic relapse, tumour progres-
sion, poor response to chemotherapy and a decrease in
survival [40, 77, 80]. Endostatin is an endogenous angio-
genesis inhibitor, produced by tumours itself, involved in
repression of neo-angiogenesis and is commonly expressed
in human OS samples. It can also induce apoptosis in
endothelial cells. Given its important role in angiogenesis,
it was hypothesised that Endostatin could impair OS
tumour growth and metastasis [18, 77, 81, 82]. However, in
a murine model of OS lung metastasis, Endostatin failed to
induce tumour shrinkage in the lungs, although, it did
retard growth of lung nodules. Treatment with this drug
will not cure OS patients, but it may result in stable met-
astatic disease with prolonged survival [83].
(Pre)clinical studies: Proliferation
Pharmacologic inhibition of the GH/IGF-1 axis and thus
IGF-1R pathways has been explored. However, whereas
there is evidence that IGF-1R signalling is important to
primary OS growth, the extent to which IGF-1R (inhibi-
tion) could regulate OS metastases is not clear. In 2002,
Mansky et al. [78] performed a phase I study in OS patients
with metastatic and/or recurrent disease testing the clinical
efﬁcacy of the Somatostatin analog OncoLar. OncoLar was
shown to signiﬁcantly reduce circulating IGF-1 in patients.
However, all patients enrolled showed disease progression.
More recently, fully humanised monoclonal antibodies
(mABs) directed against the IGF-1R were tested in pre-
clinical and clinical setting. In vivo IGF-1R inhibition with
monoclonal antibodies induced growth retardation in sub-
cutaneous models of OS [79, 84]. Whether this growth
delay will also be shown in OS metastasis is unknown.
The SARC-011 clinical trial is evaluating the treatment
effect of R1507, a mAB targeting the IGF-1R in patients
with recurrent sarcomas, including OS (clinicaltrials.gov/
NCT00642941). In another clinical trial the efﬁcacy of
SCH717454, also targeting the IGF-1R, is evaluated in
relapsed OS patients. In this trial, both inoperable patients
and patients in whom metastasectomy is feasible are
included. The latter group will be treated pre- and post-
metastasectomy and might, apart from tumour response
rate, give information about progression-free survival
(clinicaltrials.gov/NCT00617890).
Conclusion
In conclusion, this review summarises potential molecular
alterations that contribute to metastasis in OS and gives an
overview of (pre)clinical efforts to develop new therapeutic
targets for the treatment of metastatic OS. In spite of these
efforts, OS metastasis is not yet well understood and there
has been little evolvement in the treatment of this disease
over the last decade. We hypothesise that certain molecular
alterations seen in metastatic cells can also contribute to
resistance to chemotherapy, and targeting these features
might enhance the efﬁcacy of current treatments. Further
unravelling the biology of OS metastasis will hopefully
provide new insights to be used as a rational basis for
innovative metastasis directed treatments for OS.
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